TickerGuard
Buy Day today: Neutral (51) Mixed market breadth · no major macro event
RPRX

Royalty Pharma Plc

Healthcare · Biotechnology

58.40$ -0.9% vs. previous close Closing price · As of: Sep 18, 2026

Statements

Income Statement

Royalty Pharma Plc (RPRX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 674 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement RPRX
Line item Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 LTM
536 596 568 537 565 594 568 579 609 622 631 674 2,536
277 77 584 6.0 228 164 127 204 1.3 1.2 1.2 268 272
536 596 568 537 565 594 568 579 609 622 629 406 2,267
51 0.5 0.5 0.5 0.5 0.5 51 301 51 51 40 98 239
57 59 58 55 57 68 111 180 119 164 159 162 604
385 -17 642 268 -170 232 34 369 182 234 -3.1 273 685
151 613 -74 270 735 362 534 210 427 388 632 133 1,581
46 47 44 49 67 66 65 69 80 94 94 94 361
122 718 -4.3 194 806 334 433 91 444 356 468 81 1,350
50 223 -9.1 92 262 126 60 156 142 173
72 494 4.8 102 544 208 238 30 288 214 295 18 815
168 765 40 243 873 400 499 159 525 451 563 176 1,716

LTM = last twelve months (sum of the four most recent quarters).

Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?